SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Frequently asked questions
What sector does SymBio Pharmaceuticals Limited (SYMQY) operate in?
SymBio Pharmaceuticals Limited belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is SymBio Pharmaceuticals Limited (SYMQY) current stock price?
As of the latest data, SymBio Pharmaceuticals Limited stock price is $0.37, with a previous close of $0.37.
What is SymBio Pharmaceuticals Limited (SYMQY) current market capitalization?
SymBio Pharmaceuticals Limited market cap is approximately 29.33 million.
What is SymBio Pharmaceuticals Limited (SYMQY) Earnings Per Share (EPS)?
The trailing EPS is -$0.60.
What is SymBio Pharmaceuticals Limited (SYMQY) EBITDA?
SymBio Pharmaceuticals Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.31 billion.
Does SymBio Pharmaceuticals Limited (SYMQY) pay dividends?
No. SymBio Pharmaceuticals Limited does not pay a dividend.
What is SymBio Pharmaceuticals Limited (SYMQY) beta (volatility) score?
SymBio Pharmaceuticals Limited has a beta of 0.525, indicating lower volatility than the overall market.